Dr. O'Neill, a medical oncologist, joins Mirna with 15 years of
therapeutic and diagnostic product development experience, with senior
leadership roles at global pharmaceutical companies, including Sanofi,
Dr. O'Neill will be assuming the role of Chief Medical Officer from Dr. Sinil Kim, who joined Mirna's executive team in 2013 and led the design and management of Mirna's Phase 1 clinical trial of MRX34, its lead product candidate and the first microRNA therapeutic in clinical development in cancer.
"We are excited that Vince is joining the Mirna team as we prepare to
advance MRX34 into two Phase 2 trials later this year. His extensive
leadership in product development across all phases of clinical study as
well as his background in molecular pathology and translational research
will significantly enhance our efforts as we move into this next stage
of our Company's growth," said Dr.
Dr. O'Neill received his M.D. and his
About Mirna Therapeutics, Inc.
Mirna is a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The Company was founded in 2007 and is located in Austin, Texas.
For more information, visit www.mirnarx.com.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Mirna, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including
statements regarding our pre-clinical and clinical activity and results
of our clinical development program, including the projected timing and
nature of Phase 2 studies of MRX34; and our beliefs regarding our
potential for growth. Such forward-looking statements involve
substantial risks and uncertainties that could cause our clinical
development program, future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the uncertainties inherent in the clinical drug development
process, including the outcomes of clinical trials, the regulatory
approval process, our substantial dependence on MRX34, our
commercialization plans and efforts and other matters that could affect
the availability or commercial potential of our product candidates.
Mirna undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to our business in
general, see our Annual Report on Form 10-K filed with the
News Provided by Acquire Media